Current Vascular Pharmacology
Title:Editorial (No-reflow After Primary Coronary Interventions: How to Prevent and How to Treat it?)
Volume: 11 Issue: 2
Author(s): Giampaolo Niccoli
Affiliation:
Export Options
About this article
Cite this article as:
Niccoli Giampaolo, Editorial (No-reflow After Primary Coronary Interventions: How to Prevent and How to Treat it?), Current Vascular Pharmacology 2013; 11 (2) . https://dx.doi.org/10.2174/1570161111311020012
DOI https://dx.doi.org/10.2174/1570161111311020012 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac Protection via Metabolic Modulation: An Emerging Role for Incretin-Based Therapies?
Cardiovascular & Hematological Agents in Medicinal Chemistry Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Phytochemical Genistein in the Regulation of Vascular Function: New Insights
Current Medicinal Chemistry Pharmacotherapeutic Approach to Prevent or Treat Chronic Allograft Nephropathy
Current Drug Targets - Cardiovascular & Hematological Disorders The Roles of Cytochrome P450 in Ischemic Heart Disease
Current Drug Metabolism Carbon Monoxide-Releasing Molecules: A Pharmacological Expedient to Counteract Inflammation
Current Pharmaceutical Design Comparison of Artemisia annua Bioactivities between Traditional Medicine and Chemical Extracts
Current Bioactive Compounds Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design Rapid Profiling and Identification of Vitexin Metabolites in Rat Urine, Plasma and Faeces after Oral Administration Using a UHPLC-Q-Exactive Orbitrap Mass Spectrometer Coupled with Multiple Data-mining Methods
Current Drug Metabolism Physically Cross-linked Hydrogels of β -cyclodextrin Polymer and Poly(ethylene glycol)-cholesterol as Delivery Systems for Macromolecules and Small Drug Molecules
Current Drug Delivery Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future
Current Pharmaceutical Design The role of NADPH Oxidase in Vascular Disease – Hypertension, Atherosclerosis & Stroke
Current Pharmaceutical Design Uric Acid and Oxidative Stress
Current Pharmaceutical Design Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Apoptosis: A Potential Therapeutic Target for Retinal Degenerations
Current Neurovascular Research Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology PPARs as Drug Targets to Modulate Inflammatory Responses?
Current Drug Targets - Inflammation & Allergy Gene Therapy with Transcription Factor Decoy Oligonucleotides as a Potential Treatment for Cardiovascular Diseases
Current Drug Targets Cell Cycle Arrest as a Therapeutic Target of Acute Kidney Injury
Current Protein & Peptide Science